SP100030

SP100030 is an inhibitor of gene transcription mediated by NF-kappaB and activator protein-1 (AP-1). It inhibits NF-kappaB- and AP-1-mediated transcription in a reporter assay using Jurkat T cells (IC50 = 0. µM for both) and decreases IL-2 and IL-8 levels in Jurkat T cells (IC50 = 0. µM for both). SP100030 (20 mg/kg per day for three days) reduces eosinophil and T cell infiltration into bronchoalveolar lavage fluid (BALF) and reduces Ap-1 and phosphorylated Ap-1 levels in isolated lung tissue in an ovalbumin-sensitized rat model of asthma. It prevents tumor-induced decreases in skeletal muscle, brown adipose tissue, spleen, kidney, and heart mass in a rat model of cachexia when administered at a dose of 1 mg/kg per day. SP100030 (10 mg/kg per day) inhibits bleomycin-induced decreases in body weight, increases in wet-dry lung weight ratio, and increases in lung total protein, myeloperoxidase (Mpo), elastase, collagen, and IL-1beta levels in a mouse model of pulmonary fibrosis.. Solulibility: DMSO: Sparingly soluble: 1-10 mg/mL: Ethanol: Sparingly soluble: 1-10 mg/mL.